Want to join the conversation?
Medical device maker $BSX received FDA approval for SYNERGY Bioabsorbable Polymer Drug-Eluting Stent (BP-DES) for the treatment of CAD. $BSX to commence commercialization of the first & only BP-DES in the US immediately. Four-year EVOLVE trial of BP-DES data showed a continued 0% stent thrombosis rate & a low 1.1% rate of lesion revascularization.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)